

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Padmavathi V. Baskar  
Art Unit : 1645  
Applicants : Beat A. Imhof, Michel Aurrand-Lions  
Serial No. : 10/579,105  
Filed : February 8, 2007  
Conf. No. : 3550  
For : Angiogenesis Inhibiting Molecules and Their Use in the Treatment and  
Diagnosis of Cancer

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

TERMINAL DISCLAIMER

Sir:

The owner, Merck Serono S.A., of 100% interest in the above-identified patent application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as shortened by any terminal disclaimer, of prior Patent No. 7,642,341. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination

certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer.

I am the attorney of record.

The fee of \$140.00 under 37 CFR 1.20(d) was paid at the time this Terminal Disclaimer was filed. The Commissioner is hereby authorized to charge any other fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

April 1, 2010  
Date

Frank C. Eisenschenk  
Frank C. Eisenschenk, Ph.D.  
Patent Attorney  
Reg. No. 45,332  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/jb